Volume 16, Number 1—January 2010
Research
Severe Pneumonia Associated with Pandemic (H1N1) 2009 Outbreak, San Luis Potosí, Mexico
Alejandro Gómez-Gómez
, Martin Magaña-Aquino, Christian A. García-Sepúlveda, Uciel R. Ochoa-Pérez, Reynaldo Falcón-Escobedo, Andreu Comas-García, Saray Aranda-Romo, Hugo I. Contreras-Treviño, Paulina V. Jiménez-Rico, Mario A. Banda-Barbosa, Félix Dominguez-Paulin, J. Mario Bernal-Blanco, Luis F. Pérez-González, and Daniel E. Noyola
, Martin Magaña-Aquino, Christian A. García-Sepúlveda, Uciel R. Ochoa-Pérez, Reynaldo Falcón-Escobedo, Andreu Comas-García, Saray Aranda-Romo, Hugo I. Contreras-Treviño, Paulina V. Jiménez-Rico, Mario A. Banda-Barbosa, Félix Dominguez-Paulin, J. Mario Bernal-Blanco, Luis F. Pérez-González, and Daniel E. Noyola
Table 3
Demographic, clinical, and laboratory features on admission of patients with pandemic (H1N1) 2009 and nonconfirmed influenza pneumonia cases during the pandemic (H1N1) 2009 outbreak, San Luis Potosí, Mexico*
| Characteristic | Pandemic (H1N1) 2009 (n = 11) | Nonconfirmed influenza (n = 32) | p value |
|---|---|---|---|
| Demographic features | |||
| Male sex | 5 (45.5) | 20 (62.5) | 0.48 |
| Age, y, mean (SD) | 34 (10.97) | 39.47 (14) | 0.25 |
| Resident of San Luis Potosí municipality |
5 (45.5) |
20 (62.5) |
0.73 |
| Clinical features | |||
| Presence of underlying conditions | |||
| Obesity (BMI >30)† | 4 (40) | 16 (57.1) | 0.47 |
| Diabetes | 2 (18.2) | 4 (12.5) | 0.64 |
| Other conditions‡ | 3 (27.3) | 4 (12.5) | 0.35 |
| Days from symptom onset to admission, mean (SD) | 5.36 (2.5) | 6.72 (3.13) | 0.2 |
| Duration of symptoms at the onset of dyspnea, d, mean (SD) | 2.73 (1.19) | 3.91 (1.92) | 0.06 |
| Pneumonia severity index (PORT score) |
2.82 (1.47) |
2.81 (1.15) |
0.99 |
| Symptoms | |||
| Fever | 11 (100) | 32 (100.0) | NA |
| Headache | 10 (90.9) | 31 (96.9) | 0.45 |
| Cough | 11 (100) | 31 (96.9) | 1 |
| Myalgias | 9 (81.8) | 32 (100.0) | 0.06 |
| Arthralgias | 10 (90.9) | 30 (93.8) | 1 |
| Dyspnea | 11 (100) | 25 (78.1) | 0.16 |
| Rhinorrea | 8 (72.7) | 25 (78.1) | 0.69 |
| Malaise | 6 (54.5) | 11 (34.4) | 0.29 |
| Blood-streaked sputum | 3 (27.3) | 13 (40.6) | 0.49 |
| Diarrhea | 1 (9.1) | 7 (21.9) | 0.66 |
| Pleuritic chest pain | 1 (9.1) | 5 (15.6) | 1 |
| Vomiting |
2 (18.2) |
2 (6.3) |
0.27 |
| Physical examination findings on admission | |||
| BMI, mean (SD) | 29.17 (6.48) | 31.22 (5.4) | 0.34 |
| Respiratory rate, bpm, mean (SD) | 28.44 (4.91) | 28.31 (7.24) | 0.92 |
| Crackles | 0.03 | ||
| Unilateral | 4 (36.4) | 2 (6.3) | |
| Bilateral | 7 (63.6) | 30 (93.8) | |
| Wheezing |
5 (45.5) |
18 (56.3) |
0.73 |
| Laboratory features | |||
| Total leukocyte count on admission (x 109/L), median (SD) | 8.81 (6.1) | 6.81 (4.13) | 0.23 |
| Platelet count (x 109/L), mean (SD)§ | 173.6 (61.48) | 227 (216.24) | 0.45 |
| C-reactive protein, mg/dL, mean (SD) | 14.51 (8.45) | 18.74 (16.22) | 0.41 |
| Creatinine, mg/dL, median (SD) | 1.24 (0.87) | 1.11 (0.75) | 0.13 |
| Creatine phosphokinase, U/L, mean (SD) | 376.78 (439.22) | 462.2 (507.27) | 0.65 |
| Lactate dehydrogenase, U/L, median (SD)§ | 952 (674.72) | 1089.31 (602.32) | 0.54 |
| AST, mg/dL, median (range)¶ | 43 (19–76) | 69 (18–249) | 0.07 |
| ALT, mg/dL, median (range)# | 29 (13–55) | 43 (13–177) | 0.05 |
*Values are no. (%) unless otherwise indicated. BMI, body mass index; bpm, breaths per minute; PORT, Pneumonia Patient Outcomes Research Team (www.ahrq.gov/clinic/pneuclin.htm); NA, not available; AST, aspartate aminotransferase; ALT; alanine transaminase.
†Data available for 38 patients.
‡Includes chronic renal failure, systemic lupus erythematosus, pregnancy, cardiac disorder, seizure disorder.
§Data available for 42 patients.
¶Data available for 41 patients.
#Data available for 40 patients.
Page created: March 31, 2011
Page updated: March 31, 2011
Page reviewed: March 31, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.